GlassScriptPhysician profile
Susan E Adams
NPI 1922004332
$3,009.70
in general payments reported to CMS, 2019-2025
29 companies · $867 in 2025
The $867 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $102 · 2023: $858 · 2024: $1,183 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,818 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,818.10 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $407.38 | 2023-2025 | |
| Abbvie INC. | $349.05 | 2022-2025 | Vraylar, Ubrelvy, Viberzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.03 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $212.53 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.59 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $142.32 | 2023-2024 | |
| Astellas Pharma US INC | $142.03 | 2023-2024 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $129.82 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Almatica Pharma LLC | $122.60 | 2023-2025 | Loreev Xr |
| Abbott Laboratories | $115.50 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $112.20 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $101.42 | 2022-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $101.13 | 2023-2024 | Rybelsus, Ozempic |
| Aesculap, INC. | $88.39 | 2024 | Aesculap |
| Pfizer INC. | $87.71 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $75.76 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $52.15 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $39.41 | 2024 | Eliquis |
| Phathom Pharmaceuticals, INC. | $38.75 | 2024 | Voquezna |
| Neurocrine Biosciences, INC. | $24.73 | 2025 | |
| Xeris Pharmaceuticals, INC. | $24.07 | 2024 | Gvoke Hypopen |
| Collegium Pharmaceutical, INC. | $23.68 | 2025 | Jornay Pm |
| Alkermes, INC. | $22.45 | 2025 | Aristada, Lybalvi |
| Indivior INC. | $22.04 | 2024 | Sublocade |
| Antares Pharma, INC. | $21.06 | 2023 | Xyosted, Nocdurna, Tlando |
| Takeda Pharmaceuticals U.S.A., INC. | $19.00 | 2025 | Trintellix |
| Azurity Pharmaceuticals, INC. | $17.63 | 2025 | Alvesco |
| Medtronic, INC. | $15.47 | 2024 | Minimed 780g |
| Philips North America LLC | $13.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.